N.J.S.A. 54:10A-5.24

Comprehensive Analysis of N.J.S.A. 54:10A-5.24 and the New Jersey Research and Development Tax Credit Framework

N.J.S.A. 54:10A-5.24 provides a 10% corporation business tax credit for increased qualified research expenses and basic research payments conducted within the state of New Jersey. This statutory provision incentivizes innovation by allowing corporate taxpayers to reduce their state tax liability based on the incremental growth of their local research and development investments.

The legal architecture of the New Jersey Research and Development (R&D) Tax Credit is a cornerstone of the state’s Innovation Economy strategy. It serves as a sophisticated fiscal mechanism designed to attract and retain high-growth industries such as biotechnology, pharmaceuticals, and advanced computing. By offering a direct credit against the Corporation Business Tax (CBT), the state effectively subsidizes a significant portion of the technical risk inherent in scientific discovery and technological improvement. This credit is not merely a passive deduction but a proactive tool that requires a nuanced understanding of both federal definitions and state-specific limitations. Since its inception, the credit has evolved from a static model tethered to historical federal rules to a modern, dynamic framework that aligns with current Internal Revenue Code (IRC) standards while maintaining a strict geographical boundary on eligible activities.

The Statutory Architecture of N.J.S.A. 54:10A-5.24

To understand the legal meaning of N.J.S.A. 54:10A-5.24, one must dissect its component parts as established by the New Jersey Legislature. The statute is organized into subsections that define the calculation, the limitations on double-counting, the permanence of the credit, and specific considerations for small businesses.

Subsection (a): The Core Grant of Credit

The primary grant of the credit is found in subsection (a), which mandates that a taxpayer shall be allowed a credit against the tax imposed pursuant to section 5 of P.L.1945, c. 162. The amount of this credit is twofold: it equals 10% of the excess of qualified research expenses (QREs) for the privilege period over a calculated base amount, and 10% of basic research payments. A critical legal nuance within this subsection is the New Jersey Performance requirement. The statute explicitly states that terms such as qualified research expenses and basic research shall include only expenditures for research conducted in this state. This creates a high evidentiary burden for taxpayers to prove that the activities were physically performed within New Jersey borders, regardless of where the entity is headquartered or where the final product is marketed.

Subsection (b): Credit Priority and Exclusivity

Subsection (b) outlines the hierarchy of tax credits and the carryover provisions. It explicitly prohibits the use of the same expenditures for multiple New Jersey tax credits. For instance, if a company uses expenses to calculate the R&D credit, those same expenses cannot be used for the Manufacturing Equipment and Employment Investment Tax Credit or the New Jobs Investment Tax Credit. This prevents the artificial inflation of tax benefits through the overlapping of incentive programs. Furthermore, subsection (b) establishes the standard seven-year carryforward period for unused credits, although this is modified for priority industries under supplemental statutes.

Subsection (c): Decoupling from Federal Expiration

A unique feature of the New Jersey R&D credit is its permanence as established in subsection (c). This provision states that no provision terminating Section 41 of the federal Internal Revenue Code shall apply to the New Jersey credit. This means that even if the United States Congress were to allow the federal R&D credit to sunset or were to repeal it entirely, the New Jersey credit would remain in force, using the federal rules that existed prior to such termination as the basis for the state calculation.

Subsection (d): Small Business Protections

Introduced for privilege periods beginning on or after January 1, 2020, subsection (d) provides a critical bridge for small businesses that elect to take the federal payroll tax credit in lieu of the income tax credit under IRC Sections 41(h) and 3111(f). Under federal rules, such an election disallows the use of those same expenses for the federal income tax credit. However, the New Jersey statute clarifies that for the purposes of calculating the state credit, these expenditures remain fully allowable. This ensures that New Jersey startups are not penalized for utilizing federal payroll relief.

Statutory Subsection	Primary Legal Function	Key Application
54:10A-5.24(a)	Establishes credit rate and base	10% credit on excess QREs and basic payments.
54:10A-5.24(b)	Defines carryover and exclusivity	7-year carryforward; prohibits double-dipping with other NJ credits.
54:10A-5.24(c)	Ensures state permanence	Credit survives even if federal IRC § 41 is repealed.
54:10A-5.24(d)	Small business alignment	Allows NJ credit even if federal payroll credit is elected.

The Evolution and Modernization of the Credit

The context of N.J.S.A. 54:10A-5.24 cannot be fully appreciated without examining the significant legislative overhaul that occurred for privilege periods beginning on or after January 1, 2018. Prior to this modernization, the New Jersey credit was essentially frozen in time, tethered to the version of IRC Section 41 that was in effect on June 30, 1992.

This divergence created an immense administrative burden for taxpayers. For decades, companies were forced to maintain two separate sets of R&D records: one following current federal law for their IRS filings, and one reconstructing 1992-era rules for their New Jersey CBT-100 returns. The 2018 reform (P.L. 2018, c. 48) solved this by conforming the state credit to current federal standards, including the adoption of the Alternative Simplified Credit (ASC) method. This alignment allows businesses to use the same methodologies for state and federal purposes, provided the expenses are limited to New Jersey-based activities.

The modernization also addressed the treatment of research expenditures under IRC Section 174. While federal law now requires the amortization of R&D expenses over five or fifteen years, New Jersey has provided guidance through Tax Bulletin TB-114 and subsequent notices that allow for a more taxpayer-friendly same-year deduction for New Jersey-qualified research expenditures when the credit is claimed. This divergence from federal amortization requirements represents a significant advantage for New Jersey-based firms, as it preserves immediate cash flow that would otherwise be deferred under federal tax law.

Defining Qualified Research in a New Jersey Context

The application of N.J.S.A. 54:10A-5.24 relies heavily on the definition of qualified research, which New Jersey borrows from federal IRC Section 41(d). To qualify, an activity must satisfy a cumulative Four-Part Test.

The Four-Part Test Framework

Technological in Nature: The activity must fundamentally rely on the principles of physical science, biological science, engineering, or computer science. This excludes research in the social sciences, arts, or humanities.

Permitted Purpose: The research must be intended to develop a new or improved business component, which is defined as a product, process, software, technique, formula, or invention to be held for sale, lease, or use in the taxpayer’s trade or business. The focus must be on improving functionality, performance, reliability, or quality.

Elimination of Uncertainty: The taxpayer must intend to discover information that would eliminate uncertainty concerning the capability or method for developing or improving the business component, or the appropriate design of that component.

Process of Experimentation: Substantially all of the activities must constitute a process of experimentation, which involves the systematic evaluation of alternatives through modeling, simulation, or systematic trial and error.

Eligible Expense Categories

Under N.J.S.A. 54:10A-5.24, only specific costs associated with these qualified activities are includable in the credit calculation. These expenses must be paid or incurred by the taxpayer during the privilege period in carrying on any trade or business.

• Wages: This includes salaries, wages, and even certain stock options paid to employees for qualified services. Qualified services encompass not only the direct performance of research but also the direct supervision or direct support of such research. If an employee spends 80% or more of their time on qualified services, the substantially all rule allows for 100% of their wages to be included.
• Supplies: Any tangible property, other than land or improvements to land, that is consumed or used in the conduct of qualified research. This often includes materials used for prototypes or chemicals used in laboratory testing.
• Contract Research: 65% of the amount paid or incurred by the taxpayer to any person (other than an employee) for qualified research conducted on the taxpayer’s behalf. For New Jersey purposes, the third-party research must be performed within the state.
• Computer Rentals: Any amount paid to another person for the right to use computers in the conduct of qualified research. This typically applies to cloud computing or high-performance computing clusters used for simulations.
• Basic Research Payments: 100% of cash payments to qualified organizations (such as universities or scientific research organizations) for basic research performed under a written agreement. For privilege periods beginning after January 1, 2018, this also includes payments to energy research consortia.

Excluded Activities and Limitations

The New Jersey Division of Taxation, through N.J.A.C. 18:7-3.23 and 18:7-3.23A, explicitly identifies activities that do not qualify for the credit, even if they appear technological:

• Research conducted after the beginning of commercial production of the business component.
• Adaptation of an existing product or process to a particular customer’s need (customization vs. innovation).
• Reverse engineering or duplication of an existing product or process.
• Efficiency surveys, management studies, or market research.
• Research relating to internal-use software, unless it meets a higher standard of innovation.
• Research funded by another person or government entity (the taxpayer must bear the economic risk).

Local Revenue Office Guidance: Technical Bulletins and Administrative Rules

The New Jersey Division of Taxation provides the operational details for N.J.S.A. 54:10A-5.24 through its Technical Bulletins (TB) and the New Jersey Administrative Code (N.J.A.C.). These sources are essential for compliance as they interpret how the statutory language applies to specific corporate structures and accounting methods.

Tax Bulletin TB-114: The Definitive Guide

TB-114 (Revised December 2023 and updated in late 2025) provides the Division’s position on several critical issues. A key insight from this bulletin is the state’s stance on federal conformity. The Division clarifies that while New Jersey leverages federal IRC Section 41 rules, it does not adopt every federal limitation. For instance, New Jersey does not require the Section 280C reduction of the research expense deduction when the credit is claimed, which is a significant departure from federal practice that benefits the taxpayer’s bottom line.

TB-114 also addresses the treatment of S corporations. While the R&D credit is available to S corporations, it can only be used to offset the entity-level CBT liability. Unlike the federal credit, the New Jersey R&D credit does not pass through to the individual shareholders via a K-1. Any unused credit must be carried forward by the S corporation itself.

N.J.A.C. 18:7-3.23A: Modern Calculation Methods

This section of the Administrative Code governs credits for privilege periods beginning on and after January 1, 2018. It mandates that a taxpayer must use the same calculation method for New Jersey purposes that was used for federal purposes on their federal return. This means if a taxpayer elects the ASC method on IRS Form 6765, they must also use the ASC method on New Jersey Form 306.

N.J.A.C. 18:7-3.23A also provides a safe harbor for companies that conduct research both inside and outside of New Jersey. If a taxpayer cannot precisely isolate the New Jersey-specific QREs using their primary accounting records, they may use an allocation method to estimate the New Jersey portion, provided the method is reasonable and consistently applied.

TB-107 and TB-108(R): The 2023 Reforms

Recent legislation (P.L. 2023, c. 96) has further refined the CBT landscape. TB-107 and TB-108(R) discuss the shift to a bright-line economic nexus standard. Effective for privilege periods ending on and after July 31, 2023, a corporation has nexus with New Jersey if its New Jersey-source receipts exceed $100,000 or if it has 200 or more transactions with New Jersey customers. This is highly relevant for the R&D credit because out-of-state companies that previously did not file in New Jersey may now find themselves subject to the CBT—and thus eligible to claim credits for any research they conduct within the state’s borders.

Calculation Methodologies: The Regular Method vs. ASC

The determination of the excess amount over the base is the most complex part of the R&D credit. New Jersey offers two paths, mirroring the federal options.

The Regular Credit Method

The Regular Method is based on the taxpayer’s research intensity relative to its gross receipts. It is often more beneficial for established companies with a long history of research in New Jersey.

Calculate the Fixed-Base Percentage: This is the ratio of aggregate QREs to aggregate gross receipts for a specific historical period (usually 1984–1988). This percentage is capped at 16%.

Determine Average Annual Gross Receipts: The average of the taxpayer’s New Jersey-source gross receipts for the four preceding taxable years.

Establish the Base Amount: The product of the fixed-base percentage and the average annual gross receipts. The base amount cannot be less than 50% of the current year’s QREs.

Calculate the Credit: 10% of the current QREs that exceed the base amount.

The Alternative Simplified Credit (ASC) Method

The ASC method is generally preferred by startups or companies whose historical records are unavailable. It does not require gross receipts data.

Determine the Three-Year Average: Sum the New Jersey QREs for the three preceding taxable years and divide by six.

Calculate the Excess: Current year New Jersey QREs minus the three-year average.

Apply the Credit Rate: 10% of that excess.

If a taxpayer had no QREs in any of the three preceding years, the credit is calculated as 6% of the current year’s QREs, although the New Jersey statute still allows for a 10% rate on the excess once a base is established.

Feature	Regular Method	ASC Method
Historical Data Required	1984–1988 QREs and Gross Receipts	Prior 3 years of QREs only.
Gross Receipts Impact	High (Average of prior 4 years)	None.
Base Amount Floor	50% of current QREs	Based on 3-year QRE history.
Common User	Established corporations	Startups and volatile spenders.

Priority Industry Extensions: N.J.S.A. 54:10A-5.24b

A critical nuance for the high-tech sector is the extension of the carryforward period from seven years to fifteen years. This is codified in N.J.S.A. 54:10A-5.24b and applies to businesses conducting research in specific fields.

Qualified Priority Fields

• Advanced Computing: Hardware and software innovations from handhelds to supercomputers.
• Advanced Materials: Engineered materials like ceramics, high-value metals, and polymers.
• Biotechnology: Molecular and sub-atomic research into biological systems.
• Electronic Device Technology: Microelectronics, semiconductors, and digital imaging.
• Environmental Technology: Alternative energy and environmental cleanup.
• Medical Device Technology: FDA-regulated therapeutic or diagnostic products (excluding pharmaceuticals).

This extension acknowledges the long burn rate and lengthy development cycles in these industries. A biotechnology company may spend fifteen years in research and clinical trials before generating a profit; the fifteen-year carryforward ensures their early-stage research credits do not expire before they have a tax liability to offset.

Monetization: The NJEDA Tax Certificate Transfer Program

Perhaps the most unique application of N.J.S.A. 54:10A-5.24 in context is the ability for unprofitable companies to sell their credits for cash. This is managed by the New Jersey Economic Development Authority (NJEDA) through the Technology Business Tax Certificate Transfer Program.

Program Mechanics and Limits

Unprofitable technology and biotechnology companies with fewer than 225 U.S. employees can apply to surrender their unused R&D credits and net operating losses (NOLs). These credits are then sold to other New Jersey corporate taxpayers who can use them to offset their own CBT liability.

• Sales Price: The credits must be sold for at least 80% of their face value.
• Program Cap: There is an annual statewide cap of $75 million for this program.
• Individual Cap: A firm is subject to a $20 million lifetime cap on the amount of benefits it can sell.
• Economic Impact: In 2024, approximately $30 million in credits were successfully disbursed through this program, providing essential non-dilutive capital to New Jersey startups.

Detailed Example: Multi-Year Credit Application

To illustrate the meaning and application of N.J.S.A. 54:10A-5.24, consider JerseyGenomics, a Newark-based biotechnology startup.

Year 1: Baseline Establishment

In 2022, JerseyGenomics has $1,000,000 in New Jersey-qualified research expenses. They are unprofitable and pay the $2,000 minimum CBT. They cannot use the credit yet, but they file Form 306 to establish the credit amount. Under the ASC method (assuming they are new), they might qualify for a 6% credit of $60,000, which they carry forward.

Year 2: Expansion

In 2023, the company expands its Newark lab and incurs $2,000,000 in NJ QREs.

• ASC Base Calculation: (Year 1 QREs of $1,000,000 + $0 + $0) / 6 = $166,667.
• Excess QREs: $2,000,000 – $166,667 = $1,833,333.
• Current Credit: 10% of $1,833,333 = $183,333.
• Total Carryforward: $60,000 (from Year 1) + $183,333 = $243,333.

Year 3: Monetization

In 2024, JerseyGenomics still has no tax liability but needs cash to hire three new scientists. They apply to the NJEDA program. They sell their $243,333 in credits to an established insurance company for 90% of their value ($218,999 in cash). JerseyGenomics receives the cash immediately, while the insurance company uses the credits to offset its own New Jersey CBT.

Statistics and Economic Outlook

The fiscal impact of the R&D tax credit is a vital metric for state policymakers. For the 2025 fiscal year, the credit is projected to cost the state approximately $359 million in foregone revenue. However, this is viewed as an investment. Studies of similar programs suggest that for every dollar of tax credit awarded, a significant portion is reinvested directly into the state’s economy through high-wage employment and local supply chain spending.

Data from 2024 and 2025 indicates that the Information sector (including data processing, web hosting, and computer infrastructure) is becoming a major user of the credit, with average awards reaching $191,000 per recipient. Despite the presence of large corporate claimants, the vast majority of credit recipients (97.2%) are small to mid-sized businesses receiving less than $500,000 in credits.

Fiscal Year	Projected Expenditure	Key Industry Trends
2023	~$300 million	Post-COVID recovery in pharma research.
2024	~$330 million	Growth in “Information” and AI sectors.
2025	$359 million	Expected surge in green-tech and biotech.

Combined Groups and the Finnigan Rule

For privilege periods ending on and after July 31, 2023, New Jersey has transitioned from the Joyce rule to the Finnigan rule for combined groups. This has a profound impact on how R&D credits are shared.

Under the Finnigan rule, if any member of a combined group has nexus with New Jersey, the entire group is essentially treated as a single taxpayer for the purpose of the receipts factor and credit eligibility. This means that R&D credits generated by one member of the group can be used more freely to offset the tax liability of other members of the group, even if the other members do not have a separate nexus with New Jersey. However, the credits still cannot be used to reduce any member’s tax below the statutory minimum.

Audit Defense and Documentation Requirements

Given the high value of these credits, the New Jersey Division of Taxation frequently audits R&D claims. The burden of proof is entirely on the taxpayer to demonstrate that the four-part test was met for every project and that every dollar of wage or supply was New Jersey-based.

Required Recordkeeping

Project Descriptions: Contemporaneous documents explaining the technical uncertainty and the process of experimentation.

Wage Nexus: Payroll records that identify the physical location of the employee. For remote or hybrid workers, this is a major area of audit risk.

Third-Party Contracts: Agreements that prove the taxpayer maintained substantial rights to the research and bore the financial risk.

Consistency: Proof that the calculation method used for New Jersey matches federal Form 6765.

Final Thoughts: The Strategic Imperative of N.J.S.A. 54:10A-5.24

N.J.S.A. 54:10A-5.24 is more than a line item on a tax return; it is a complex, multifaceted incentive that defines New Jersey’s relationship with the global innovation sector. By aligning state tax policy with federal definitions while offering unique benefits like the 15-year carryforward and the NJEDA transfer program, New Jersey has created one of the most attractive environments for R&D in the United States.

For the corporate taxpayer, the meaning of the statute lies in its ability to de-risk investment. Whether through the direct reduction of CBT liability or the monetization of credits via sale, N.J.S.A. 54:10A-5.24 provides a critical source of capital that fuels the next generation of scientific breakthroughs. As the state continues to refine its bright-line nexus and combined reporting rules, the R&D tax credit will remain a central pillar of New Jersey’s fiscal and economic landscape. Successful navigation of this framework requires not only technical accounting proficiency but also a deep appreciation of the legislative intent to keep New Jersey at the forefront of global innovation.